Hans Lindgren

Hans Lindgren

affiliated with the university, Senior Consultant, PhD

    If you made any changes in Pure these will be visible here soon.

    Personal profile



    Peripheral arterial disease (PAD) with focus on intermittent claudication, and results of invasive treatment on both intermittent claudication and critical limb ischemia – with outcome focus on HRQoL. One study cohort with IC, randomized between invasive treatment or best medical treatment (BMT) alone has now 1 year follow up data (showing superior results for invasive treatment) presented in an scientific paper, and is about to be followed for both 2 and 5 years. Health economics in this cohort is beeing calculated to evaluate the cost effectiveness of the treatment. Another studycohort investigating the impact of CWP on HRQoL in PAD patients has presented 1 year data showing improvment of HRQoL even in patients with CWP, this cohort will soon be investigated in a longer follow-up. 2D perfusion is a new method for evaluating the perfusion in the foot before and after invasive treatment in patients with CLI, we are running a pilot study on this now. PAE is a new method for treatment of bening prostae hyperplasia (BPH) with minimal invasive endovascular methods, we are planning a prospective study on this method compared to open surgery


    UKÄ subject classification

    • Surgery


    • Peripheral arterial disease, Intermittent claudication, Endovascular treatment, Health related quality of life (HRQoL), Chronic widespread pain (CWP), SWEDEPAD, 2D perfusion, Prostate arteral embolisation (PAE)


    Dive into the research topics where Hans Lindgren is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
    • 1 Similar Profiles


    Recent external collaboration on country/territory level. Dive into details by clicking on the dots or